All In Biotech

Drug Trial Radar · NCT06510452

Antibiotic Prophylaxis in Metabolic Bariatric Surgery

Efficacy of Antibiotic Prophylaxis in Metabolic Bariatric Surgery: A Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Jul 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 3,352 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

3,352

Planned (sponsor's estimate)

Start

Oct 1, 2024

Primary completion

Dec 1, 2025

Study completion Apr 1, 2026

Sponsor

Sponsor type
Government (non-federal)
First posted
Jul 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

SUMMARY Rationale: Prophylactic antibiotics in laparoscopic surgeries, including Metabolic Bariatric Surgery (MBS), are routinely provided to reduce postoperative infections, especially at wound incision sites. However, since incisional wound infections in laparoscopic MBS are rare and morbidity is very low, the benefit of antibiotic prophylaxis is questionable. Objective: Evaluate the non-inferiority of omitting antibiotic prophylaxis in MBS. Compare postoperative outcomes between Group A (no antibiotics) and Group B (standard antibiotic care) to determine if omission increases complications, particularly wound infections. Study Design: Randomized controlled trial (RCT), double-blind. Study Population: Patients with obesity eligible for MBS. Intervention: * Group A (No Antibiotic Prophylaxis): Undergo MBS without antibiotics to test safety regarding postoperative complications, focusing on surgical site infections (SSIs). * Group B (Standard Antibiotic Prophylaxis): Receive standard one-time antibiotics before incision. Main Study Parameters/Endpoints: Compare the incidence of incisional and organ/space SSIs within six weeks post-surgery between Group A and Group B to determine if omitting antibiotics affects infection rates.

Conditions

  • Antibiotic Reaction
  • Wound Infection Superficial
  • Wound Infection Deep
  • Bariatric Surgery Candidate
  • Complication,Postoperative

Interventions

  • 2000 mg of CefazolinDrug

    receive 2000 mg of Cefazolin and 500 mg of Metronidazole IV dissolved in 100 ml NACL0.9%.

  • 500 mg of Metronidazole IVDrug

    receive 2000 mg of Cefazolin and 500 mg of Metronidazole IV dissolved in 100 ml NACL0.9%.

  • NACL 0.9% 100 mlDrug

    receive 100 ml NACL0.9% without any antibiotics in it.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of incidence of postoperative wound infections in both treatment armsTime frame: until 6 weeks post operative

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Madina Women's Hospital

    Alexandria, Egypt

  • WeightWorks clinics

    Amersfoort, Utrecht, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.